Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2019

View Archived Issues

Basophils protect against sepsis

Kinase plays role in radiation resistance

Antihypertensive drug enhances ovarian cancer chemotherapy

FDA clears IND for ALLO-501 program

Primary endpoint met in pivotal phase III dengue vaccine TIDES study

MMV and DNDi launch a new project to accelerate the discovery of new drugs for pandemic diseases

Discovery of multireceptor ligands as novel class of atypical antipsychotic drugs for schizophrenia

GlaxoSmithKline presents new CREB-2 inhibitors

U.S. Department of Health & Human Services patents fatty acid derivatives

New PD-1/PD-L1 interaction inhibitors described by Rijksuniversiteit Groningen

New beta-lactamase inhibitors discovered at Sumitomo Dainippon Pharma

Targeting NP1/MICAL3/CRMP2/Numb axis in breast cancer

Researchers develop B. pseudomallei-induced melioidosis mouse model to characterize T-cell responses

Shanghai Institute of Materia Medica discloses PARP-1/2 inhibitors

CAP-1002 demonstrates safety and efficacy in phase I/II HOPE-Duchenne study

Coagulation factor XI inhibitors identified at Sichuan Kelun-Biotech Biopharmaceutical

Phase IIb study of SB-623 for motor deficits associated with chronic ischemic stroke misses endpoint

Orphazyme releases full data from phase II/III study of arimoclomol in Niemann-Pick disease type C

Allakos reports phase II data on AK-002 in cholinergic urticaria and symptomatic dermographism

CPSF1 mutations tied to early-onset high myopia

IMPACT Therapeutics identifies wee1-like protein kinase inhibitors

Phase III study of oral contraceptive Estelle meets primary efficacy endpoint

Genentech to discontinue phase III CREAD 1 & 2 studies of crenezumab in early sporadic Alzheimer's

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...